Skip to content

US · BNTX · BIOTECHNOLOGY

BioNTech SE (BNTX) intrinsic value and stock valuation

$80.96as of 2026-11-21 · Mkt cap 23.16B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioNTech SE DCF and intrinsic value

InvestorsCraft values BNTX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from BNTX’s statements →

BioNTech SE Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Mainz, RP 55131 biontech.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$2.76B+41.7% 5y CAGRd
20172025
Net income
-$-1.09B
20172025
Free cash flow
$269.8M
20172025
Total equity
$19.2B+69.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$2.76B$2.75B$3.82B$17.3B$19B
Operating income-$-623.87M-$-1.31B$690.4M$12.6B$15.3B
Net income-$-1.09B-$-665.3M$930.3M$9.43B$10.3B
EPSd-$-4.51M-$-2.77M$3.83M$37.8M$39.6M
Operating cash flow$438M$207.7M$5.37B$13.6B$889.7M
Capital expenditure-$-168.19M-$-452.3M-$-705.5M-$-363.3M-$-154M
Free cash flow$269.8M-$-244.6M$4.67B$13.2B$735.7M
Total assets$22B$22.5B$23B$23.3B$15.8B
Total debt$267.3M$254.2M$219.1M$212.2M$301.5M
Net debt-$-7.4B-$-9.51B-$-11.44B-$-13.66B-$-1.39B
Total equity$19.2B$19.4B$20.2B$20.1B$11.9B
Cash and short-term investments$14.8B$16.8B$16.5B$14.1B$2.07B
Income statement
20252024202320222021
Revenue$2.76B$2.75B$3.82B$17.3B$19B
Cost of revenue$616.5M$541.3M$599.8M$3B$2.91B
Gross profit$2.14B$2.21B$3.22B$14.3B$16.1B
Research and development expenses$2.02B$2.25B$1.78B$1.54B$949.2M
Selling, general and administrative expenses$698.2M$599M$557.7M$541.2M$327.2M
Other expenses$44M$670.9M$188M-$-405.3M-$-495M
Operating expenses$2.76B$3.52B$2.53B$1.67B$781.4M
Cost and expenses$3.38B$4.07B$3.13B$4.67B$3.69B
Interest income$252.2M$0.00$351.3M$47.4M$1.56M
Interest expense$13.6M$13.2M$7.76M$15.8M$5.63M
Depreciation and amortization$367.7M$298M$183.4M$123.3M$75.2M
Ebitda-$-628M-$-367.1M$1.38B$13.1B$15B
Operating income-$-623.87M-$-1.31B$690.4M$12.6B$15.3B
Total other income/expenses, net-$-385.46M$636.6M$495.7M$311.4M-$-237.4M
Income before tax-$-1.01B-$-677.7M$1.19B$13B$15B
Income tax expense$81.9M-$-12.4M$255.8M$3.52B$4.75B
Net income-$-1.09B-$-665.3M$930.3M$9.43B$10.3B
Weighted average shares outstanding$241.7M$240.4M$240.6M$243.3M$244M
Weighted average diluted shares outstanding$241.7M$240.4M$242.7M$249.8M$259.7M
Balance sheet
20252024202320222021
Cash and short-term investments$14.8B$16.8B$16.5B$14.1B$2.07B
Net receivables$984.5M$1.52B$2.34B$7.15B$12.4B
Inventory$110.7M$283.3M$357.7M$439.6M$502.5M
Total current assets$16.1B$18.8B$19.5B$21.9B$15.1B
Property, plant and equipment, net$1.29B$1.18B$971.6M$821.1M$520.4M
Goodwill and intangible assets$1.97B$1.17B$1.17B$219.7M$202.4M
Long-term investments$2.49B$1.25B$1.18B$80.2M$21.3M
Total non-current assets$5.84B$3.73B$3.48B$1.36B$758.5M
Total assets$22B$22.5B$23B$23.3B$15.8B
Accounts payable$534.7M$426.7M$354M$204.1M$160M
Short-term debt$52.2M$39.5M$28.1M$36M$129.9M
Deferred revenue$754.6M$294.9M$353.3M$77.1M$186.1M
Total current liabilities$2.14B$2.52B$2.07B$2.95B$3.48B
Long-term debt$215.1M$214.7M$191M$176.2M$171.6M
Deferred revenue, non-current$88M$183M$398.5M$48.4M$9M
Total non-current liabilities$621.8M$595.4M$689.9M$272.9M$455.5M
Capital lease obligations$185.2M$0.00$0.00$0.00$0.00
Total liabilities$2.76B$3.12B$2.76B$3.22B$3.94B
Common stock$258.9M$248.6M$248.6M$248.6M$246.3M
Retained earnings$18B$19.1B$19.8B$18.8B$9.88B
Accumulated other comprehensive income (loss)-$-1.46B-$-1.33B-$-984.6M-$-848.9M$93.9M
Total equity$19.2B$19.4B$20.2B$20.1B$11.9B
Total investments$9.65B$8.28B$6.06B$269.6M$402.9M
Total debt$267.3M$254.2M$219.1M$212.2M$301.5M
Net debt-$-7.4B-$-9.51B-$-11.44B-$-13.66B-$-1.39B
Cash flow statement
20252024202320222021
Net income-$-1.09B-$-677.7M$1.19B$13B$15B
Depreciation and amortization$367.7M$298M$183.4M$123.3M$75.2M
Stock-based compensation$0.00$100.9M$51.4M$108.6M$93.9M
Change in working capital$516.6M$1.22B$5.57B$4.52B-$-10.73B
Accounts receivable$1.04B$387.7M$5.37B$4.37B-$-11.81B
Inventory$170.9M$74.5M$81.9M$62.9M-$-438.4M
Accounts payable-$-695.23M$758.4M$118.9M$85.7M$1.52B
Net cash provided by operating activities$438M$207.7M$5.37B$13.6B$889.7M
Investments in property, plant and equipment-$-719.44M-$-286.5M-$-250.1M-$-329.2M-$-127.5M
Acquisitions, net$183.3M$0.00-$-336.9M$0.00-$-20.8M
Net cash used for investing activities-$-2.37B-$-2.08B-$-6.95B-$-35.3M-$-566.1M
Common stock issued$0.00$0.00$0.00$110.5M$160.9M
Common stock repurchased$0.00$0.00-$-738.5M-$-986.4M$0.00
Dividends paid$0.00$0.00$0.00-$-484.3M$0.00
Net cash used for financing activities-$-50.81M-$-45.9M-$-778.6M-$-1.42B$94.2M
Net change in cash-$-931.17M-$-1.9B-$-2.21B$12.2B$482.5M
Cash at end of period$7.67B$9.76B$11.7B$13.9B$1.69B
Operating cash flow$438M$207.7M$5.37B$13.6B$889.7M
Capital expenditure-$-168.19M-$-452.3M-$-705.5M-$-363.3M-$-154M
Free cash flow$269.8M-$-244.6M$4.67B$13.2B$735.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioNTech SE

        BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

        CEO
        Ugur Sahin
        Employees
        7.81K
        Beta
        1.32

        Explore

        Frequently asked questions

        What is the intrinsic value of BioNTech SE (BNTX)?

        BioNTech SE (BNTX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BNTX undervalued?

        BNTX trades at a price of $80.96 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.